Cullinan Oncology Llc Stock Performance
| CGEM Stock | USD 12.22 0.36 2.86% |
The firm shows a Beta (market volatility) of 2.15, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cullinan Oncology will likely underperform. At this point, Cullinan Oncology LLC has a negative expected return of -0.57%. Please make sure to confirm Cullinan Oncology's kurtosis, and the relationship between the maximum drawdown and day median price , to decide if Cullinan Oncology LLC performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cullinan Oncology LLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (3.15) | Five Day Return (21.44) | Year To Date Return 15.06 | Ten Year Return (59.26) | All Time Return (59.26) |
Last Split Factor 2:1 | Last Split Date 2009-08-31 |
1 | Disposition of 176 shares by Jennifer Michaelson of Cullinan Oncology at 13.11 subject to Rule 16b-3 | 08/30/2024 |
2 | Disposition of 319 shares by Jeffrey Trigilio of Cullinan Oncology at 13.11 subject to Rule 16b-3 | 09/04/2024 |
3 | Disposition of 8000 shares by Jennifer Michaelson of Cullinan Oncology at 18.09 subject to Rule 16b-3 | 09/05/2024 |
4 | Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus | 09/17/2024 |
5 | Cullinan Therapeutics Files Investigational New Drug Application with FDA for CLN-978 for Treatment of Systemic Lupus Erythematosus - Lupus Foundation of Americ... | 09/23/2024 |
6 | Renaissance Technologies LLC Has 7.36 Million Position in Cullinan Therapeutics, Inc. - MarketBeat | 09/26/2024 |
7 | Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to S... | 10/16/2024 |
8 | Cullinan Therapeutics Research Coverage Started at UBS Group | 10/24/2024 |
9 | Vanguard Group Incs Strategic Acquisition in Cullinan Therapeutics Inc | 11/05/2024 |
10 | Cullinan Therapeutics Q3 Earnings Snapshot | 11/07/2024 |
11 | Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | 11/14/2024 |
12 | Cullinan Therapeutics Is In A Good Position To Deliver On Growth Plans | 11/20/2024 |
| Begin Period Cash Flow | 156.2 M |
Cullinan |
Cullinan Oncology Relative Risk vs. Return Landscape
If you would invest 1,826 in Cullinan Oncology LLC on August 24, 2024 and sell it today you would lose (604.00) from holding Cullinan Oncology LLC or give up 33.08% of portfolio value over 90 days. Cullinan Oncology LLC is currently does not generate positive expected returns and assumes 3.6841% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Cullinan, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cullinan Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cullinan Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cullinan Oncology LLC, and traders can use it to determine the average amount a Cullinan Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1542
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CGEM |
Estimated Market Risk
| 3.68 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.57 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cullinan Oncology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cullinan Oncology by adding Cullinan Oncology to a well-diversified portfolio.
Cullinan Oncology Fundamentals Growth
Cullinan Stock prices reflect investors' perceptions of the future prospects and financial health of Cullinan Oncology, and Cullinan Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cullinan Stock performance.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | 156.87 M | ||||
| Shares Outstanding | 58.23 M | ||||
| Price To Earning | 5.23 X | ||||
| Price To Book | 1.17 X | ||||
| Price To Sales | 26.88 X | ||||
| Gross Profit | 18.94 M | ||||
| EBITDA | (190.34 M) | ||||
| Net Income | (153.16 M) | ||||
| Cash And Equivalents | 611 M | ||||
| Cash Per Share | 13.40 X | ||||
| Total Debt | 3.59 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 10.04 X | ||||
| Book Value Per Share | 10.80 X | ||||
| Cash Flow From Operations | (134.28 M) | ||||
| Earnings Per Share | (2.84) X | ||||
| Market Capitalization | 732.5 M | ||||
| Total Asset | 484.18 M | ||||
| Retained Earnings | (200.86 M) | ||||
| Working Capital | 452.05 M | ||||
About Cullinan Oncology Performance
By examining Cullinan Oncology's fundamental ratios, stakeholders can obtain critical insights into Cullinan Oncology's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Cullinan Oncology is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.30) | |
| Return On Capital Employed | (0.42) | (0.40) | |
| Return On Assets | (0.32) | (0.30) | |
| Return On Equity | (0.34) | (0.32) |
Things to note about Cullinan Oncology LLC performance evaluation
Checking the ongoing alerts about Cullinan Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cullinan Oncology LLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cullinan Oncology generated a negative expected return over the last 90 days | |
| Cullinan Oncology has high historical volatility and very poor performance | |
| Net Loss for the year was (153.16 M) with profit before overhead, payroll, taxes, and interest of 18.94 M. | |
| Cullinan Oncology LLC currently holds about 611 M in cash with (134.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cullinan Oncology has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Cullinan Therapeutics Is In A Good Position To Deliver On Growth Plans |
- Analyzing Cullinan Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cullinan Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Cullinan Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cullinan Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cullinan Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cullinan Oncology's stock. These opinions can provide insight into Cullinan Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.